Dendrite Gives Shanghai SINE Medicine Company the Ability to Meet the Unique Needs of Chinese Pharmaceutical Market; Increased Penetration in Chinese Market Illustrates Growing Global Embrace of Dendrite Solutions

Business Wire, June 2, 2006

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of pharmaceutical industry solutions, today announced a comprehensive three-year agreement to provide SINE Pharmaceutical Company Co., Ltd, a subsidiary of Shanghai Pharmaceutical Group Co., Ltd (SPGC) and pioneer in China's growing pharmaceutical market, with components of Dendrite's Sales Solutions. SINE will deploy Dendrite's j-forceNET - Express(TM) and j-force Analyzer(TM), designed to help pharmaceutical companies increase the productivity of their sales forces in China. In addition, Dendrite will provide SINE with product support including implementation and software maintenance services and standard technical support. SINE will roll out Dendrite's solutions in September 2006. E[acute accent]The agreement with SINE comes as China's pharmaceutical market is experiencing tremendous growth, driven and supported by significant sales force investments from some of the world's top pharmaceutical companies. A 2002 report by the Boston Consulting Group projected that China would emerge as the fifth-largest pharmaceutical market in the world by the year 2010. E[acute accent]SINE selected Dendrite's Sales Solutions based largely on Dendrite's ability to effectively serve China's pharmaceutical market. China's existing technological architecture prevents sales representatives in rural areas from leveraging the same communication channels with the same efficiency as sales representatives in metropolitan areas. With Dendrite's solution flexibility, representatives in Shanghai can access information on mobile devices while representatives, without the same level connectivity, can access the same solutions on a wired system. E[acute accent]"With China's pharmaceutical industry growing at a rapid pace, it is critical for SINE to achieve the highest sales force productivity possible to remain at the forefront of the market," said Peikang Lu, President of SPGC Sine Pharmaceutical Company. "With Dendrite's local office in Shanghai and its proven expertise in serving the global pharmaceutical industry, selecting Dendrite's Sales Solutions was an obvious choice to fit for our needs. With Dendrite we expect to improve the productivity and efficiency of our growing sales force." E[acute accent]"To deal with increasing consolidation and integration needs, domestic pharmaceutical groups are speeding up the pace of adopting western-style sales management practices," said Chin-Shung Tsau, Dendrite vice president business development and marketing for Asia-Pacific. "Dendrite's deep pharmaceutical focus and years of global pharmaceutical experience will enable domestic pharma customers in China to gain a competitive edge. " E[acute accent]"Our relationship with SINE reinforces our deep commitment to serving the pharmaceutical market in China," said Jean-Paul Modde, president Dendrite Asia Pacific. "Dendrite has the deep domain and regional market expertise to provide the right mix of solutions and services to help growing companies like SINE succeed in the pharmaceutical industry,"

E[acute accent]About Dendrite

E[acute accent]Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global, pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

E[acute accent]Note: Dendrite is a registered trademark of Dendrite International, Inc.

E[acute accent]This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.